---
layout: default
title: Fluocinolone Acetonide
parent: 僅模型預測 (L5)
nav_order: 718
evidence_level: L5
indication_count: 4
---

# Fluocinolone Acetonide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the drug-repurposing evaluation report format supplied in the system prompt to convert the Evidence Pack into the structured Markdown report.

# Fluocinolone Acetonide: From Corticosteroid Dermatologic Therapy to Hypertrophic Lichen Planus

## One-Sentence Summary

Fluocinolone acetonide is a fluorinated synthetic glucocorticoid; the specific original indication is not recorded in the available regulatory data for this drug. The TxGNN model predicts it may be effective for **Hypertrophic Lichen Planus**, but this specific drug–disease pairing currently has **no clinical trials** and **no published literature** to support it — the prediction rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no approved-indication text is on file (no Taiwan/US licenses recorded; original MOA is also flagged as a data gap) |
| Predicted New Indication | Hypertrophic Lichen Planus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

> **Note on related candidates:** Three other TxGNN-predicted indications appear in this evidence pack for the same drug — annular atrophic lichen planus, lichen planus pigmentosus, and lichen planus pemphigoides (score ≈99.3–99.4%). Of these, **lichen planus pemphigoides** has reached decision stage S1 ("Research Question") because two related topical corticosteroids (fluocinonide, clobetasol propionate — same pharmacologic class) have published trial data in oral vesiculoerosive/lichen planus–spectrum disease. This is class-level, not drug-specific, evidence, but it strengthens the overall biological plausibility of the lichen-planus/topical-steroid link discussed below.

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for fluocinolone acetonide itself is not available in this evidence pack (flagged as a data gap). Based on the information that is available, fluocinolone acetonide is a **fluorinated synthetic glucocorticoid**. Pharmacologically, it acts through glucocorticoid receptor–mediated suppression of pro-inflammatory cytokines and T-cell–mediated immune responses. This mechanism is the pharmacological basis for using topical corticosteroids to treat lichen planus, which is itself a T-cell–mediated inflammatory mucocutaneous disease.

Hypertrophic lichen planus is a clinical variant of lichen planus characterized by thickened, hyperkeratotic plaques, and its inflammatory pathophysiology overlaps substantially with classic lichen planus. Because topical corticosteroids are a mainstay treatment across the lichen planus disease spectrum, extending fluocinolone acetonide's anti-inflammatory/immunosuppressive action to this variant is mechanistically plausible.

However, this reasoning is currently **class-level, not drug-specific**: there are no clinical trials or publications in this evidence pack that test fluocinolone acetonide directly in hypertrophic lichen planus (or in any lichen planus subtype). The supporting literature identified elsewhere in this evidence pack (see note above) concerns related corticosteroids, not fluocinolone acetonide itself. The prediction should therefore be treated as a hypothesis generated purely by the TxGNN model at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No marketing authorizations are on file for fluocinolone acetonide in this evidence pack — market status is recorded as **Not Marketed**, with zero licenses.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This drug–disease pairing (fluocinolone acetonide / hypertrophic lichen planus) is supported only by a TxGNN model score (99.42%), with zero clinical trials and zero published literature specific to this combination. Evidence level is L5 (model prediction only), which does not meet the bar to advance to clinical feasibility review.

**To proceed, the following is needed:**
- Direct clinical or preclinical evidence for fluocinolone acetonide (not just the broader corticosteroid class) in lichen planus or hypertrophic lichen planus specifically
- Confirmed mechanism of action data for fluocinolone acetonide (currently a data gap)
- Original approved indication and regulatory history (currently missing/empty in this evidence pack)
- TFDA/US label warnings, contraindications, and drug interaction data (currently all marked as data gaps — blocking issue for any S1 safety review)
- Clarification of current market status, since the drug is recorded as not marketed and has zero authorizations on file
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

